DrugPipeline.net has announced the addition of “Choroidal Neovascularization - Pipeline Review, H1 2018” research report to their website www.DrugPipeline.net

Bangalore, India -- (SBWire) -- 06/27/2018 --Choroidal Neovascularization - Pipeline Review, H1 2018, provides an overview of the Choroidal Neovascularization (Ophthalmology) pipeline landscape.

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes ant-VEGF agents, laser photocoagulation and photodynamic therapy.

Report Highlights
Choroidal Neovascularization - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Choroidal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Choroidal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization (Ophthalmology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Choroidal Neovascularization (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Choroidal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 47 pages "Choroidal Neovascularization - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Choroidal Neovascularization - Overview, Choroidal Neovascularization - Therapeutics Development, Choroidal Neovascularization - Therapeutics Assessment, Choroidal Neovascularization - Companies Involved in Therapeutics Development, Choroidal Neovascularization - Drug Profiles, Choroidal Neovascularization - Dormant Projects, Appendix. This report Covered Companies - F. Hoffmann-La Roche Ltd, Formycon AG, Iconic Therapeutics Inc, Isarna Therapeutics GmbH, Lupin Ltd, Mabion SA, NovelMed Therapeutics Inc, Noxxon Pharma AG, Promedior Inc.

For more information Visit at: https://www.drugpipeline.net/global-markets-direct/choroidal-neovascularization-pipeline-review-h1-2018

Find all Pharma and Healthcare Reports at - https://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/lysophosphatidic-acid-receptor-1-lysophosphatidic-acid-receptor-edg-2-or-1

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/somatostatin-receptor-type-2-srif1-or-sstr2-pipeline-review-h1-2018

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.